Literature DB >> 14581542

Contrasting use of CCR5 structural determinants by R5 and R5X4 variants within a human immunodeficiency virus type 1 primary isolate quasispecies.

Yanjie Yi1, Anjali Singh, Farida Shaheen, Andrew Louden, ChuHee Lee, Ronald G Collman.   

Abstract

Macrophagetropic R5 human immunodeficiency virus type 1 (HIV-1) isolates often evolve into dualtropic R5X4 variants during disease progression. The structural basis for CCR5 coreceptor function has been studied in a limited number of prototype strains and suggests that R5 and R5X4 Envs interact differently with CCR5. However, differences between unrelated viruses may reflect strain-specific factors and do not necessarily represent changes resulting from R5 to R5X4 evolution of a virus in vivo. Here we addressed CCR5 domains involved in fusion for a large set of closely related yet functionally distinct variants within a primary isolate swarm, employing R5 and R5X4 Envs derived from the HIV-1 89.6(PI) quasispecies. R5 variants of 89.6(PI) could fuse using either N-terminal or extracellular loop CCR5 sequences in the context of CCR5/CXCR2 chimeras, similar to the unrelated R5 strain JRFL, but R5X4 variants of 89.6(PI) were highly dependent on the CCR5 N terminus. Similarly, R5 89.6(PI) variants and isolate JRFL tolerated N-terminal CCR5 deletions, but fusion by most R5X4 variants was markedly impaired. R5 89.6(PI) Envs also tolerated multiple extracellular domain substitutions, while R5X4 variants did not. In contrast to CCR5 use, fusion by R5X4 variants of 89.6(PI) was largely independent of the CXCR4 N-terminal region. Thus, R5 and R5X4 species from a single swarm differ in how they interact with CCR5. These results suggest that R5 Envs possess a highly plastic capacity to interact with multiple CCR5 regions and support the concept that viral evolution in vivo results from the emergence of R5X4 variants with the capacity to use the CXCR4 extracellular loops but demonstrate less-flexible interactions with CCR5 that are strongly dependent on the N-terminal region.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14581542      PMCID: PMC254272          DOI: 10.1128/jvi.77.22.12057-12066.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Substitutions in a homologous region of extracellular loop 2 of CXCR4 and CCR5 alter coreceptor activities for HIV-1 membrane fusion and virus entry.

Authors:  D J Chabot; C C Broder
Journal:  J Biol Chem       Date:  2000-08-04       Impact factor: 5.157

2.  Causal relationships between HIV-1 coreceptor utilization, tropism, and pathogenesis in human thymus.

Authors:  R D Berkowitz; S Alexander; J M McCune
Journal:  AIDS Res Hum Retroviruses       Date:  2000-07-20       Impact factor: 2.205

Review 3.  An overview of the determinants of CCR5 and CXCR4 co-receptor function.

Authors:  Tatjana Dragic
Journal:  J Gen Virol       Date:  2001-08       Impact factor: 3.891

4.  Heterogeneous spectrum of coreceptor usage among variants within a dualtropic human immunodeficiency virus type 1 primary-isolate quasispecies.

Authors:  A Singh; R G Collman
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  Human immunodeficiency virus type 1 pathogenesis in SCID-hu mice correlates with syncytium-inducing phenotype and viral replication.

Authors:  D Camerini; H P Su; G Gamez-Torre; M L Johnson; J A Zack; I S Chen
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

6.  Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities.

Authors:  A Brelot; N Heveker; M Montes; M Alizon
Journal:  J Biol Chem       Date:  2000-08-04       Impact factor: 5.157

7.  Concordant utilization of macrophage entry coreceptors by related variants within an HIV type 1 primary isolate viral swarm.

Authors:  A Singh; Y Yi; S N Isaacs; D L Kolson; R G Collman
Journal:  AIDS Res Hum Retroviruses       Date:  2001-07-01       Impact factor: 2.205

8.  Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization.

Authors:  Q Hu; J O Trent; G D Tomaras; Z Wang; J L Murray; S M Conolly; J M Navenot; A P Barry; M L Greenberg; S C Peiper
Journal:  J Mol Biol       Date:  2000-09-15       Impact factor: 5.469

9.  Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope-mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolates.

Authors:  D J Chabot; P F Zhang; G V Quinnan; C C Broder
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

10.  Entry of R5X4 and X4 human immunodeficiency virus type 1 strains is mediated by negatively charged and tyrosine residues in the amino-terminal domain and the second extracellular loop of CXCR4.

Authors:  F Kajumo; D A Thompson; Y Guo; T Dragic
Journal:  Virology       Date:  2000-06-05       Impact factor: 3.616

View more
  4 in total

1.  Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages.

Authors:  Kieran Cashin; Michael Roche; Jasminka Sterjovski; Anne Ellett; Lachlan R Gray; Anthony L Cunningham; Paul A Ramsland; Melissa J Churchill; Paul R Gorry
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

2.  Constrained use of CCR5 on CD4+ lymphocytes by R5X4 HIV-1: efficiency of Env-CCR5 interactions and low CCR5 expression determine a range of restricted CCR5-mediated entry.

Authors:  Lamorris M Loftin; Martha F Kienzle; Yanjie Yi; Benhur Lee; Fang-Hua Lee; Lachlan Gray; Paul R Gorry; Ronald G Collman
Journal:  Virology       Date:  2010-04-09       Impact factor: 3.616

3.  Preferential use of CXCR4 by R5X4 human immunodeficiency virus type 1 isolates for infection of primary lymphocytes.

Authors:  Yanjie Yi; Farida Shaheen; Ronald G Collman
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

4.  Evolution of CCR5 use before and during coreceptor switching.

Authors:  Mia Coetzer; Rebecca Nedellec; Janelle Salkowitz; Sherry McLaughlin; Yi Liu; Laura Heath; James I Mullins; Donald E Mosier
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.